Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities

Neurology

Volumn 74, Issue 21, 2010, Pages 1724-1731

  Pallud, J ^a,d   Varlet, P ^a,b   Devaux, B ^a   Geha, S ^a,b   Badoual, M ^c   Deroulers, C ^c   Page, P ^a   Dezamis, E ^a   Daumas Duport, C ^a,b   Roux, F X ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; KI 67 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STEREOTACTIC BIOPSY; TUMOR CELL; TUMOR GROWTH;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY; BRAIN; BRAIN NEOPLASMS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; OLIGODENDROGLIOMA; PROTONS; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 77953007933     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e04264     Document Type: Article

References (39)

1. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 2006;60:380-383.
2. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003;53:524-528.
3. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol 2005;4:476-486.
4. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hop-man AH, Twijnstra A. Supratentorial grade II astrocy-toma: biological features and clinical course. Lancet Neurol 2003;2:395-403.
5. Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D. Surgery insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 2007;3:628-639.
6. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62: 753-764.
7. Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med 2008;358:18-27.
8. Devaux B, Turak B, Roujeau T, et al. Adult supratento-rial oligodendrogliomas. Surgical treatment: indications and techniques [in French]. Neurochirurgie 2005;51: 353-367.
9. Duffau H. New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity\a review. J Neurooncol 2006;79:77-115.
10. Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 2005;103:1227-1233.
11. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol 1997;34:85-101.
12. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338-1345.
13. Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry 2004;75(suppl 2):ii31-ii36.
14. Rees JH. Low-grade gliomas in adults. Curr Opin Neurol 2002;15:657-661.
15. Kelly PJ. Technology in the resection of gliomas and the definition of madness. J Neurosurg 2004;101:284-286.
16. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas part I: patterns of growth, histological diagnosis, clinical and imaging correlations\a study of 153 cases. J Neurooncol 1997;34:37-59.
17. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004;100:2622-2626.
18. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neurora-diology 1992;34:463-469.
19. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neuro-surg 1987;66:865-874.
20. Iwama T, Yamada H, Sakai N, et al. Correlation between magnetic resonance imaging and histopathology of intra-cranial glioma. Neurol Res 1991;13:48-54.
21. Ganslandt O, Stadlbauer A, Fahlbusch R, et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 2005;56:291-298.
22. Daumas-Duport C, Meder JF, Monsaingeon V, Missir O, Aubin ML, Szikla G. Cerebral gliomas: malignancy, limits and spatial configuration\comparative data from serial stereotaxic biopsies and computed tomography (a preliminary study based on 50 cases). J Neurora-diol 1983;10:51-80.
23. Daumas-Duport C, Szikla G. Definition of limits and 3D configuration of cerebral gliomas: histological data, therapeutic incidences (author's transl) [in French]. Neuro-chirurgie 1981;27:273-284.
24. Mandonnet E, Pallud J, Clatz O, et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neuro-surg Rev 2008;31:263-269.
25. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
26. Daumas-Duport C, Koziak M, Miquel C, Nataf F, Jouvet A, Varlet P. Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies [in French]. Neurochirurgie 2005;51:247-253.
27. Daumas-Duport C, Tucker ML, Kolles H, et al. Oligo-dendrogliomas part II: a new grading system based on morphological and imaging criteria. J Neurooncol 1997; 34:61-78.
28. Whittle IR. Surgery for gliomas. Curr Opin Neurol 2002; 15:663-669.
29. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligo-dendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085-2089.
30. Pirzkall A, Nelson SJ, McKnight TR, et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 2002;53:1254-1264.
31. Croteau D, Scarpace L, Hearshen D, et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated gli-oma. Neurosurgery 2001;49:823-829.
32. Giese A. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21: 1624-1636.
33. Armstrong RC, Dorn HH, Kufta CV, Friedman E, Dubois-Dalcq ME. Pre-oligodendrocytes from adult human CNS. J Neurosci 1992;12:1538-1547.
34. Geha S, Pallud J, Junier MP, et al. NG2 +/Olig2+ cells are the major cycle-related population of the adult human normal brain. Brain Pathol ePub 2009 May 22.
35. Windrem MS, Nunes MC, Rashbaum WK, et al. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat Med 2004;10:93-97.
36. Rhee W, Ray S, Yokoo H, et al. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia 2009; 57:510-523.
37. Nishiyama A, Chang A, Trapp BD. NG2+ glial cells: a novel glial cell population in the adult brain. J Neuro-pathol Exp Neurol 1999;58:1113-1124.
38. Dawson M, Levine JM, Reynolds R. NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 2000;61:471-479.
39. Stadlbauer A, Moser E, Gruber S, et al. Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas. Neuroimage 2004;23:454-461.